Atea (AVIR) news

AVIR 2Q loss/share 41c, est. loss/share 56c (2 est.)

Avir Inc. (AVIR) reported a second-quarter loss of 41 cents per share, outperforming the estimated loss of 56 cents per share according to two analyst estimates [1]. The results reflect the company’s ongoing efforts to navigate market challenges and operational adjustments. The…

Atea Pharmaceuticals - C-Forward Phase 3 trial to report top-line results in early 2027

Atea Pharmaceuticals has announced that its C-Forward Phase 3 clinical trial is expected to report top-line results in early 2027. The trial is evaluating the company’s investigational antiviral candidate for the treatment of respiratory syncytial virus (RSV) in high-risk adult patients. The study…

Atea's Bem/RZR achieves 93.9% SVR rate vs 94.8% for Sof/Vel

Atea Pharmaceuticals' Bem/RZR combination therapy demonstrated a sustained virologic response (SVR) rate of 93.9% in the treatment of chronic hepatitis C virus (HCV), slightly lower than the 94.8% SVR rate observed for Gilead Sciences' Sof/Vel regimen in comparative trials. These results come from…

Atea 2Q EBITDA NOK507.0M, est. NOK536.3M

Atea reported second-quarter earnings before interest, taxes, depreciation, and amortization (EBITDA) of NOK507.0 million, falling short of the estimated NOK536.3 million for the period. The result reflects a mixed performance across the company’s operations, with certain segments contributing to…

Atea 2Q gross sales NOK18.86B